Ligand Pharmaceuticals (LGND) has reached a roughly $740M deal to buy Xoma XOMA Royalty (XOMA) at $39 per share, people familiar with the matter told The Wall Street Journal. The companies that buy rights to drugs in exchange for funding development are expected to announce the all-cash deal as soon as Monday, according to the sources.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XOMA: